# Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases

> **NCT03656640** · — · TERMINATED · sponsor: **Octapharma** · enrollment: 60 (actual)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** Gammanorm

## Key facts

- **NCT ID:** NCT03656640
- **Lead sponsor:** Octapharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-23
- **Primary completion:** 2019-12-09
- **Final completion:** 2019-12-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656640, "Trial Assessing Safety and Efficacy of Gammanorm® in Autoimmune Diseases". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03656640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*